{"id":"https://openalex.org/W2746435463","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.3037","title":"Phase I study of vandetinib in combination with gemcitabine and oxaliplatin in advanced solid malignancies.","display_name":"Phase I study of vandetinib in combination with gemcitabine and oxaliplatin in advanced solid malignancies.","publication_year":2012,"publication_date":"2012-05-20","ids":{"openalex":"https://openalex.org/W2746435463","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.3037","mag":"2746435463"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.15_suppl.3037","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.3037","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.3037","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100396152","display_name":"Peng Wang","orcid":"https://orcid.org/0000-0003-4303-6081","observed_orcids":["https://orcid.org/0000-0003-4303-6081","https://orcid.org/0000-0002-9093-0062"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peng Wang","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015060656","display_name":"Taofeek Kunle Owonikoko","orcid":"https://orcid.org/0000-0002-7724-7728","observed_orcids":["https://orcid.org/0000-0002-7724-7728"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taofeek Kunle Owonikoko","raw_affiliation_strings":["Winship Cancer Institute, Emory University, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Winship Cancer Institute, Emory University, Atlanta, GA","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022244759","display_name":"Yan Lin","orcid":"https://orcid.org/0000-0001-8034-5946","observed_orcids":["https://orcid.org/0000-0001-8034-5946"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Lin","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050436274","display_name":"Ronald G. Stoller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald G. Stoller","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045225602","display_name":"Daniel P. Petro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel P. Petro","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061314376","display_name":"Deric M. Park","orcid":"https://orcid.org/0000-0002-8683-7340","observed_orcids":["https://orcid.org/0000-0002-8683-7340"]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deric M. Park","raw_affiliation_strings":["University of Virginia, Charlottesville, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia, Charlottesville, VA","institution_ids":["https://openalex.org/I51556381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113733729","display_name":"Ramesh K. Ramanathan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1284308235","display_name":"Translational Genomics Research Institute","ror":"https://ror.org/02hfpnk21","country_code":"US","type":"facility","lineage":["https://openalex.org/I1284308235"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramesh K. Ramanathan","raw_affiliation_strings":["Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia G. Piper Cancer Center at Scottsdale Healthcare/TGen, Scottsdale, AZ","institution_ids":["https://openalex.org/I1284308235"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083512608","display_name":"Edward Chu","orcid":"https://orcid.org/0000-0002-0908-5325","observed_orcids":["https://orcid.org/0000-0002-0908-5325"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Chu","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027371881","display_name":"Jan Hendrik Beumer","orcid":"https://orcid.org/0000-0002-8978-9401","observed_orcids":["https://orcid.org/0000-0002-8978-9401"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan Hendrik Beumer","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012316179","display_name":"Leonard Joseph Appleman","orcid":"https://orcid.org/0000-0003-4951-7388","observed_orcids":["https://orcid.org/0000-0003-4951-7388"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leonard Joseph Appleman","raw_affiliation_strings":["University of Pittsburgh Cancer Institute, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pittsburgh Cancer Institute, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"15_suppl","first_page":"3037","last_page":"3037"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.8339999914169312,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.8339999914169312,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.1145000010728836,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.004699999932199717,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9390000104904175},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":1.0},{"id":"https://openalex.org/keywords/vegfr-tyrosine-kinase-inhibitors","display_name":"VEGFR inhibitors","score":0.7250000238418579},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.7210000157356262},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7429999709129333},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8199999928474426},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.968999981880188},{"id":"https://openalex.org/keywords/deep-vein-thrombosis","display_name":"deep vein thrombosis","score":0.8700000047683716},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.8240000009536743},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.8669999837875366},{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.8550000190734863},{"id":"https://openalex.org/keywords/biliary-tract-cancer","display_name":"biliary tract cancer","score":0.7979999780654907},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6669999957084656},{"id":"https://openalex.org/keywords/ret","display_name":"RET","score":0.9409999847412109},{"id":"https://openalex.org/keywords/vegfr","display_name":"VEGFR","score":0.6010000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9284999370574951},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7398141622543335},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7107712030410767},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6686721444129944},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.6261663436889648},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.604712188243866},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5298839807510376},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5288625359535217},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.45058390498161316},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4084191620349884},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3510890007019043},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3476690649986267},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3223213851451874},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.18787157535552979}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.15_suppl.3037","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.3037","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.3037","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2205041904","https://openalex.org/W2063814508","https://openalex.org/W1964004965","https://openalex.org/W3137082226","https://openalex.org/W2058503388","https://openalex.org/W2281043402","https://openalex.org/W2046704068","https://openalex.org/W2274966411","https://openalex.org/W2898829340","https://openalex.org/W2601446410"],"abstract_inverted_index":{"3037":[0],"Background:":[1],"Vandentinib":[2],"(VAN)":[3],"is":[4],"a":[5,132,220,228,291],"tyrosine":[6],"kinase":[7,37],"inhibitor":[8],"with":[9,45,51,70,78,86,284,311],"activity":[10,327],"against":[11],"vascular":[12],"endothelial":[13],"growth":[14,25],"factor":[15,26],"receptor-2":[16],"(VEGFR-2)":[17],"and":[18,29,39,62,73,90,96,104,123,206,237,279,295,300],"3":[19,323],"(VEGFR-3)":[20],"as":[21,23,233,235,274],"well":[22,234,314],"epidermal":[24],"receptor":[27],"(EGFR)":[28],"RET":[30],"(\u2018rearranged":[31],"during":[32],"transfection\u2019).":[33],"Combinations":[34],"of":[35,66,134,137,162,181,263,319,321,336],"VEGFR":[36],"inhibitors":[38],"cytotoxic":[40],"agents":[41],"have":[42,48],"been":[43,49],"studied":[44],"interest,":[46],"but":[47],"associated":[50],"increased":[52],"toxicity.":[53],"This":[54],"phase":[55,269],"I":[56],"trial":[57],"evaluated":[58],"the":[59,187,322],"safety,":[60],"tolerability":[61],"maximum":[63,133],"tolerated":[64,315],"dose":[65,117,151,203,210,216,271],"VAN":[67,111,145,280,308],"in":[68,186,215,224,243,249,257,309,329],"combination":[69,310],"gemcitabine":[71],"(GEM)":[72],"oxaliplatin":[74],"(OX).":[75],"Methods:":[76],"Subjects":[77],"advanced":[79],"solid":[80,331],"malignancy,":[81],"\u2264":[82],"2":[83,125,176,270],"prior":[84],"regimens":[85],"adequate":[87],"hematologic,":[88],"hepatic":[89],"renal":[91],"function":[92],"were":[93,98,141,166,184,200,241],"eligible.":[94],"GEM":[95,275],"OX":[97,277],"administered":[99,113],"intravenously":[100],"at":[101,115,316],"1000":[102],"mg/m2":[103,106],"85":[105],"respectively":[107],"every":[108,175],"14":[109],"days.":[110],"was":[112,153,169,255,272,313],"orally":[114],"two":[116],"levels:":[118],"level":[119,124,152,204,211,217],"1":[120,205,218,226,258],"(200":[121],"mg)":[122,127],"(300":[126],"once":[128],"daily":[129],"continuously.":[130],"After":[131],"6":[135,163],"cycles":[136],"GEMOX,":[138],"non-progressing":[139],"patients":[140],"allowed":[142],"to":[143,155],"continue":[144],"until":[146],"progression":[147],"or":[148],"intolerance.":[149],"A":[150,179],"determined":[154],"be":[156],"tolerable":[157],"if":[158],"<2":[159],"DLTs":[160],"out":[161],"evaluable":[164],"subjects":[165,183,199,208,297],"observed.":[167],"Response":[168],"assessed":[170],"by":[171],"restaging":[172],"scan":[173],"after":[174],"cycles.":[177],"Results:":[178],"total":[180],"20":[182],"enrolled":[185,201],"study;":[188],"15":[189],"male,":[190],"5":[191],"female.":[192],"Median":[193],"age":[194],"62":[195],"years":[196],"(47-68).":[197],"Nine":[198],"on":[202,209],"11":[207],"2.":[212],"One":[213,282],"subject":[214,259,283],"experienced":[219],"deep":[221],"venous":[222],"thrombosis":[223],"cycle":[225,250],"deemed":[227],"DLT.":[229],"Thrombocytopenia":[230],"(worst-grade":[231,239],"3)":[232],"diarrhea":[236],"rash":[238],"2)":[240],"observed":[242,256],"several":[244],"patients,":[245],"without":[246],"dose-limiting":[247],"toxicity":[248],"1.":[251],"Reversible":[252],"posterior":[253],"leukoencephalopathy":[254],"following":[260],"abrupt":[261],"self-discontinuation":[262],"an":[264],"antihypertensive":[265],"mediation.":[266],"The":[267],"recommended":[268],"established":[273],"(1000mg/m2)":[276],"(85mg/m2)":[278],"(300mg).":[281],"refractory":[285,330],"small":[286],"cell":[287],"lung":[288],"cancer":[289],"had":[290],"confirmed":[292],"partial":[293],"response,":[294],"10":[296],"(pancreas-7,":[298],"bladder-2":[299],"biliary-1)":[301],"achieved":[302],"stable":[303],"disease":[304],"\u226512":[305],"weeks.":[306],"Conclusions:":[307],"GEM/OX":[312],"full":[317],"doses":[318],"each":[320],"agents.":[324],"Preliminary":[325],"anti-tumor":[326],"seen":[328],"tumors":[332],"supports":[333],"further":[334],"evaluation":[335],"this":[337],"regimen.":[338]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2017-08-31T00:00:00"}